Skip to main content
Equibles
KTTA logo

KTTA · Pasithea Therapeutics Corp. · Metrics

Track KTTA — free

Use KTTA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research KTTA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.41 0.00 (-0.56%) At close · Oct 20
Rebalance outlook locked
Market Cap
$13.70M
Shares
33.41M
Volume · Oct 20 38.5K Avg daily vol (3M) 200.56K

KTTA metrics

66 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.41
Market cap
$13.70M

Price action

20 metrics
Price change (1W)
-3.3%
Price change (30D)
-19.7%
Price change (3M)
-9.9%
Price change (6M)
-40.6%
Price change (YTD)
-68.2%
Price change (1Y)
-45.1%
Trailing year
Price change (5Y)
—
52-week high
$1.47
52-week low
$0.29
Change from 52-week high
-72.1%
Change from 52-week low
+40.4%
Annualized volatility
155.8%
Annualized volatility (3M)
65.3%
Beta
1.5
RSI (14D)
32.7
Price vs SMA 50
-17.9%
Price vs SMA 200
-37.3%
Avg volume (3M)
200,557
Relative volume
0.2
Average dollar volume
$98,838

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
33.41M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
28.2×
reciprocal yield 3.6%
P / book
0.3
reciprocal yield 363.8%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-155.4%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
-2,587.3%
Trailing 12 months
Net margin
-2,864.3%
Gross profit (TTM)
—
Operating profit (TTM)
−$23.96M
Net income (TTM)
−$21.29M
Trailing 12 months
Diluted EPS (TTM)
$-0.92
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.36
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
$-10.69
Capital expenditures per diluted share (TTM)
$0.11
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$2.39

Growth

11 metrics
Revenue growth YoY
+3,130.4%
Year over year
Net income growth YoY
—
Revenue (TTM)
$486,559
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+469.0%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-42.7%
Return on assets
-41.2%
Debt / equity
0.0
Current ratio
26.2
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
26.2
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$45.66M
Latest balance sheet
Cash & equivalents
$45.66M
Total assets
$51.71M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$17.78M
Capital expenditures (TTM)
$155,207
R&D (TTM)
$10.73M
SG&A (TTM)
$8.05M
Stock compensation (TTM)
$610,386
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
31
13F filer change QoQ
+5
Institutional ownership
51.7%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
34.1%
Private-fund adviser ownership
33.6%
Active holders' share change QoQ
+31.0%
Holder tenure
2.8
Price vs estimated holder cost
-35.5%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.7%

Short interest

3 metrics
Short interest
0.5%
Latest settlement · 1.1 days to cover
Days to cover
1.1d
Short-squeeze score
37 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1841330 CUSIP 70261F202 Visit website Investor relations